Clinical trials: completed, sponsored by SWOG Cancer Research Network
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal…
- Trial name
- NCT02438722
- Testing
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Where
- 638 sites in United States
- Volunteers
- 174 people
- Sponsor
- SWOG Cancer Research Network
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of elotuzumab and to see how well it works when given together with lenalidomide, bortezomib, and dexamethasone in treating patients with newly…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
- Trial name
- NCT01668719
- Testing
- Bortezomib, Dexamethasone, Elotuzumab
- Where
- 417 sites in United States
- Volunteers
- 142 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing…
- Trial name
- NCT00006721
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 259 sites in United States
- Volunteers
- 571 people
- Sponsor
- SWOG Cancer Research Network
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body.
- Conditions
- Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8
- Trial name
- NCT03768414
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel
- Where
- 692 sites in United States
- Volunteers
- 452 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
- Trial name
- S1216 (NCT01809691)
- Testing
- TAK-700, Bicalutamide
- Where
- 560 sites in United States
- Volunteers
- 1,313 people
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed…
- Conditions
- Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma, Unresectable Thymic Carcinoma
- Trial name
- NCT03694002
- Testing
- Carboplatin, Paclitaxel, Ramucirumab
- Where
- 254 sites in United States
- Volunteers
- 21 people
- Sponsor
- SWOG Cancer Research Network
Kidney Cancer
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- S0931 (NCT01120249)
- Testing
- everolimus
- Where
- 1,003 sites in United States, Puerto Rico
- Volunteers
- 1,545 people
- Sponsor
- SWOG Cancer Research Network
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from…
- Trial name
- NCT01359592
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 240 sites in United States
- Volunteers
- 159 people
- Sponsor
- SWOG Cancer Research Network
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body.
- Trial name
- NCT01309672
- Testing
- abiraterone acetate, Prednisone
- Where
- 205 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
This randomized phase II trial compares how well two different doses of carfilzomib work when given with dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement or has not…
- Trial name
- NCT01903811
- Testing
- Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis
- Where
- 485 sites in United States
- Volunteers
- 143 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer.
- Trial name
- NCT01224665
- Testing
- therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy
- Where
- 35 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
- Trial name
- COXEN (NCT02177695)
- Testing
- Gemcitabine, Cisplatin, Methotrexate
- Where
- 566 sites in United States
- Volunteers
- 237 people
- Sponsor
- SWOG Cancer Research Network
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04173507
- Testing
- Avelumab, Talazoparib, Talazoparib Tosylate
- Where
- 325 sites in United States
- Volunteers
- 47 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back.
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03971474
- Testing
- Docetaxel, Gemcitabine, Gemcitabine Hydrochloride
- Where
- 889 sites in United States
- Volunteers
- 166 people
- Sponsor
- SWOG Cancer Research Network
Rectal Carcinoma, Rectosigmoid Carcinoma
Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
This phase II trial studies how a diet intervention works in improving bowel dysfunction symptoms related in colon or rectal cancer survivors.
- Trial name
- NCT04205955
- Testing
- Best Practice, Dietary Intervention, Message
- Where
- 226 sites in United States, Guam
- Volunteers
- 95 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Pancreatic Adenocarcinoma
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
This partially randomized phase I/II trial studies the side effects and best dose of pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination chemotherapy and to see how well they work compared…
- Trial name
- NCT01959139
- Testing
- PEGPH20, Oxaliplatin, Leucovorin
- Where
- 154 sites in United States
- Volunteers
- 126 people
- Sponsor
- SWOG Cancer Research Network
Cancer
S1204, Viral Screening in Newly Diagnosed Cancer Patients
The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.
- Trial name
- NCT01946516
- Where
- 58 sites in United States
- Volunteers
- 3,051 people
- Sponsor
- SWOG Cancer Research Network